3,120 Shares in United Therapeutics Corporation $UTHR Acquired by Partners Capital Investment Group LLP

Partners Capital Investment Group LLP acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,120 shares of the biotechnology company’s stock, valued at approximately $1,691,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. increased its position in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 70 shares during the period. Jump Financial LLC acquired a new position in shares of United Therapeutics during the second quarter valued at $277,000. Cerity Partners LLC grew its position in shares of United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after acquiring an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia grew its position in shares of United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 105 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Down 0.0%

Shares of NASDAQ UTHR opened at $512.88 on Tuesday. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The firm’s 50-day simple moving average is $532.35 and its 200 day simple moving average is $538.04. The stock has a market cap of $22.00 billion, a P/E ratio of 18.35, a P/E/G ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.41 EPS. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on UTHR. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research report on Thursday, August 6th. Bank of America dropped their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at $23,631,280.08. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $518.39, for a total transaction of $4,924,705.00. Following the transaction, the chief executive officer owned 324,443 shares in the company, valued at $168,188,006.77. This represents a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 434,075 shares of company stock worth $233,942,595 over the last 90 days. 8.60% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.